Featuring 91 total small molecule kinase/KRAS inhibitors, 80 of which are FDA-approved, this book documents the recent scientific advances that have transformed one of medicine's most challenging areas - cancer treatment. Most of these inhibitors specifically block oncogene-induced carcinogenic proteins with results that have dramatically advanced the treatment of cancer. In addition, the structural formulas of more than 100 kinase/KRAS inhibitors in clinical trials are presented.